98%
921
2 minutes
20
Background: Positron emission tomography (PET) is increasingly applied for in vivo brown adipose tissue (BAT) research in healthy volunteers. To limit the radiation exposure, the injected F-FDG tracer dose should be as low as possible. With simultaneous PET/MR imaging, the radiation exposure due to computed tomography (CT) can be avoided, but more importantly, the PET acquisition time can often be increased to match the more extensive magnetic resonance (MR) imaging protocol. The potential gain in detected coincidence counts, due to the longer acquisition time, can then be applied to decrease the injected tracer dose. The aim of this study was to investigate the minimal F-FDG dose for a 10-min time-of-flight (TOF) PET/MR acquisition that would still allow accurate quantification of supraclavicular BAT volume and activity.
Methods: Twenty datasets from 13 volunteers were retrospectively included from a prospective clinical study. PET emission datasets were modified to simulate step-wise reductions of the original 75 MBq injected dose. The resulting PET images were visually and quantitatively assessed and compared to a 4-min reference scan. For the visual assessment, the image quality and artifacts were scored using a 5-point and a 3-point Likert scale. For the quantitative analysis, image noise and artifacts, BAT metabolic activity, BAT metabolic volume (BMV), and total BAT glycolysis (TBG) were investigated.
Results: The visual assessment showed still good image quality for the 35%, 30%, and 25% activity reconstructions with no artifacts. Quantitatively, the background noise was similar to the reference for the 35% and 30% activity reconstructions and the artifacts started to increase significantly in the 25% and lower activity reconstructions. There was no significant difference in supraclavicular BAT metabolic activity, BMV, and TBG between the reference and the 35% to 20% activity reconstructions.
Conclusions: This study indicates that when the PET acquisition time is matched to the 10-min MRI protocol, the injected F-FDG tracer dose can be reduced to approximately 19 MBq (25%) while maintaining image quality and accurate supraclavicular BAT quantification. This could decrease the effective dose from 1.4 mSv to 0.36 mSv.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977803 | PMC |
http://dx.doi.org/10.1186/s13550-020-0592-8 | DOI Listing |
Colloids Surf A Physicochem Eng Asp
October 2025
Departments of Radiology and Medical Physics, University of Wisconsin - Madison, Madison, WI 53705, USA.
Purpose: ImmunoPET imaging of PD-L1 has emerged as a promising strategy for patient stratification and treatment response monitoring in immunotherapy. This study aimed to evaluate [Zr]Zr-DFO-Durvalumab in noninvasive imaging of PD-L1 expression in non-small cell lung cancer (NSCLC) and bladder cancer.
Materials And Methods: Durvalumab was conjugated with -SCN-Bn-DFO and labeled with [Zr]Zr-oxalate, achieving high radiochemical purity (> 99 %) and stability.
Med Phys
September 2025
Imaging Program, Lawson Research Institute, London, Canada.
Background: The gastrointestinal (GI) microbiota, composed of diverse microbial communities, is essential for physiological processes, including immune modulation. Strains such as Escherichia coli Nissle 1917 support gut health by reducing inflammation and resisting pathogens. Microbial therapies using such strains may restore GI balance and offer alternatives to antibiotics, whose overuse contributes to antibiotic resistance.
View Article and Find Full Text PDFJ Vis Exp
August 2025
Department of Pathology & Laboratory Medicine and McAllister Heart Institute, University of North Carolina Chapel Hill;
Endothelial cells (ECs) play a central role in regulating fatty acid (FA) transport from the bloodstream into metabolic tissues, yet tools to quantify EC FA uptake in a reliable, scalable manner remain limited. Here, we present a rapid, quantitative, and cost-effective assay to measure FA uptake in ECs using fluorescent FA analogs (BODIPY-C12 and BODIPY-C16), which allow investigation of chain length-specific uptake dynamics in a 96-well plate format. The protocol incorporates positive (3-hydroxyisobutyrate, lactate) and negative (niclosamide) controls and is validated in both primary (HUVECs) and immortalized (EA.
View Article and Find Full Text PDFActa Oncol
August 2025
Department of Biomedicine, Aarhus University, Aarhus, Denmark; Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Denmark.
Background And Purpose: Quantification/mapping of tumor hypoxia may guide pretreatment decision-making in radiation oncology. Hypoxia-selective positron emission tomography (PET) tracers, like 18F-fluoroazomycin arabinoside (FAZA), allow assessment of hypoxia, but since hypoxia stimulates glycolysis, fluorodeoxyglucose (FDG) and hypoxia-PET may provide overlapping/similar information. Clinical dual-tracer PET studies are highly complex and remain inconclusive.
View Article and Find Full Text PDFNeuropharmacology
August 2025
Department of Neurology and National Research Center for Aging and Medicine & National Center for Neurological Disorders, State Key Laboratory of Medical Neurobiology, Huashan Hospital, Fudan University, Shanghai, 200040, China. Electronic address:
Background: Tauopathies, including Alzheimer's disease, are characterized by progressive neurodegeneration manifesting as motor and cognitive impairments. This study evaluated the therapeutic potential of semaglutide, a clinically approved glucagon-like peptide-1 receptor agonist, in the rTg4510 mouse model of tauopathy.
Methods: Starting at three months of age, rTg4510 mice and wild-type littermates received semaglutide (0.